Literature DB >> 22187175

[Two selected commercially based nucleic acid amplification tests for the diagnosis of tuberculosis].

Aleksandra Safianowska1, Renata Walkiewicz, Patrycja Nejman-Gryz, Hanna Grubek-Jaworska.   

Abstract

INTRODUCTION: This is the retrospective study on diagnostic effectiveness of two nucleic acid amplification tests: AMPLICOR Mycobacterium tuberculosis (MTB) and Xpert MTB/RIF. The first one was included into diagnostic procedure for tuberculosis from 1999 to 2009 and the second one has been used from November 2009.
MATERIAL AND METHODS: Study groups comprised 1875 samples for AMPLICOR MTB (104 were inhibited), and 213 samples for Xpert MTB/RIF.
RESULTS: The assay sensitivity was 81.9% for AMPLICOR MTB and 81.8% for Xpert MTB/RIF, and specificity was 97.2% and 99.5% respectively, as compared to the culture on Loewenstein-Jensen medium. However, sensitivity of each test correlated with Ziehl-Neelsen staining. For AFB+ samples, assay sensitivity was 97.8% for AMPLICOR MTB and 100% for Xpert MTB/RIF and for AFB- samples it was 58.1% and 50% respectively.
CONCLUSIONS: The reported results show a high diagnostic usefulness of Xpert MTB/RIF test for samples, which are positive for Ziehl-Neelsen staining.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22187175

Source DB:  PubMed          Journal:  Pneumonol Alergol Pol        ISSN: 0867-7077


  9 in total

Review 1.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

2.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

3.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

4.  Xpert MTB/RIF Ultra versus Xpert MTB/RIF for diagnosis of tuberculous pleural effusion: A systematic review and comparative meta-analysis.

Authors:  Ashutosh Nath Aggarwal; Ritesh Agarwal; Sahajal Dhooria; Kuruswamy Thurai Prasad; Inderpaul Singh Sehgal; Valliappan Muthu
Journal:  PLoS One       Date:  2022-07-11       Impact factor: 3.752

Review 5.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

Review 6.  Diagnostic Performance of Xpert MTB/RIF in Tuberculous Pleural Effusion: Systematic Review and Meta-analysis.

Authors:  Inderpaul Singh Sehgal; Sahajal Dhooria; Ashutosh Nath Aggarwal; Digambar Behera; Ritesh Agarwal
Journal:  J Clin Microbiol       Date:  2016-01-27       Impact factor: 5.948

7.  Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis.

Authors:  Simon Walusimbi; Freddie Bwanga; Ayesha De Costa; Melles Haile; Moses Joloba; Sven Hoffner
Journal:  BMC Infect Dis       Date:  2013-10-30       Impact factor: 3.090

8.  Evaluation of Susceptibility to Antimycobacterial Drugs in Mycobacterium Tuberculosis Complex Strains Isolated from Cattle in Poland.

Authors:  Monika Krajewska-Wędzina; Anna Zabost; Ewa Augustynowicz-Kopeć; Marcin Weiner; Krzysztof Szulowski
Journal:  J Vet Res       Date:  2017-04-04       Impact factor: 1.744

9.  Field evaluation of a blood based test for active tuberculosis in endemic settings.

Authors:  Aasia Khaliq; Resmi Ravindran; Syed Fahadulla Hussainy; Viwanathan V Krishnan; Atiqa Ambreen; Noshin Wasim Yusuf; Shagufta Irum; Abdul Rashid; Muhammad Jamil; Fareed Zaffar; Muhammad Nawaz Chaudhry; Puneet K Gupta; Muhammad Waheed Akhtar; Imran H Khan
Journal:  PLoS One       Date:  2017-04-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.